跳至主要内容
临床试验/NL-OMON51909
NL-OMON51909招募中不适用

A first step towards ultra-hypofractionation for unfavourable intermediate and high-risk prostate cancer: a prospective safety and feasibility study in patients with metastatic prostate cancer - UPRATE

Academisch Medisch Centrum0 个研究点目标入组 61 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
61

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Histologically proven prostate cancer
  • Radiologically proven limited metastatic disease
  • Referred to the Erasmus MC, after multidisciplinary consensus, for local
  • radiotherapy treatment, similar to the STAMPEDE trial
  • Willing to and capable of personally filling out online questionnaire
  • Signed written informed consent

排除标准

  • Previous pelvic radiotherapy or surgery for prostate cancer (excluding
  • surgery to improve urinary function in benign prostate hyperplasia, i.e.
  • trans-urethral resection of the prostate or prostatectomy according to Millin
  • or Hryntschak).
  • According to current clinical protocols, at discretion of the treating
  • physician, patients can be excluded in case of, for example, an IPSS score of
  • >20 or a prostate volume of >90ml, expecting an unacceptable rise in toxicity
  • Bilateral hip-replacement surgery, which compromises the visibility of the
  • target area on the in-room CT-scan

研究者

相似试验